Stock Research: Glenmark Pharmaceuticals

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Glenmark Pharmaceuticals

NSEI:GLENMARK INE935A01035
66
  • Value
    10
  • Growth
    100
  • Safety
    Safety
    45
  • Combined
    48
  • Sentiment
    68
  • 360° View
    360° View
    66
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. It operates in branded, generics, and OTC segments, focusing on Respiratory, Dermatology, Oncology, diabetes, cardiovascular, and oral contraceptives, with brands like RYALTRIS and SALMEX/ASTHMEX. The company develops products for markets such as India, Russia & CIS, Brazil, Asia, and Africa. In the last fiscal year, the company had a market cap of $7238 million, profits of $1050 million, and revenue of $1559 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 66 (better than 66% compared with alternatives), overall professional sentiment and financial characteristics for the stock Glenmark Pharmaceuticals are above average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for Glenmark Pharmaceuticals. The consolidated Growth Rank has a good rank of 100, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 100% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 68, which means that professional investors are more optimistic about the stock than for 68% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 45, which means that the share price of Glenmark Pharmaceuticals is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 55% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 10, which means that the company has a financing structure that is riskier than those of 90% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Index
Low Waste
Recycling
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
45 59 71 87
Growth
100 77 23 37
Safety
Safety
10 18 44 29
Sentiment
68 61 32 14
360° View
360° View
66 66 28 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
85 60 31 42
Opinions Change
13 50 38 35
Pro Holdings
n/a 25 21 26
Market Pulse
91 96 73 47
Sentiment
68 61 32 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
45 59 71 87
Growth
100 77 23 37
Safety Safety
10 18 44 29
Combined
48 54 39 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
49 64 75 89
Price vs. Earnings (P/E)
59 62 84 91
Price vs. Book (P/B)
36 59 81 87
Dividend Yield
30 18 23 40
Value
45 59 71 87
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
86 67 28 16
Profit Growth
70 98 26 53
Capital Growth
82 3 6 72
Stock Returns
91 95 95 33
Growth
100 77 23 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
27 46 26 18
Refinancing
37 28 76 84
Liquidity
23 14 38 24
Safety Safety
10 18 44 29

Similar Stocks

Discover high‑ranked alternatives to Glenmark Pharmaceuticals and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

NMDC

BSE:526371
Country: India
Industry: Steel
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.